Graduate Degree

  • University of Chicago , 1996 , Chicago , IL

Medical School

  • University of Chicago, Pritzker School of Medicine , 1998 , Chicago , IL


  • Boston Combined Residency Program (BCRP) , 1999 , Boston , MA


  • Boston Combined Residency Program (BCRP) , 2001 , Boston , MA


  • Boston Children's Hospital , 2004 , Boston , MA


  • American Board of Allergy and Immunology


Publications powered by Harvard Catalyst Profiles

  1. Development and Validation of the Asthma Exacerbation Risk Score Using Claims Data. Acad Pediatr. 2021 Jul 10. View abstract
  2. Predicting outcomes of baked egg and baked milk oral food challenges by using a ratio of food-specific IgE to total IgE. J Allergy Clin Immunol Pract. 2021 04; 9(4):1750-1752.e1. View abstract
  3. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. J Allergy Clin Immunol Pract. 2020 10; 8(9S):S16-S116. View abstract
  4. Definition, aims, and implementation of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy. 2020 08; 75(8):2115-2123. View abstract
  5. Utility of measuring tryptase levels in children and young adults. Ann Allergy Asthma Immunol. 2019 10; 123(4):398-399. View abstract
  6. Screening and Counseling for Alcohol Use in Adolescents With Chronic Medical Conditions in the Ambulatory Setting. J Adolesc Health. 2019 06; 64(6):804-806. View abstract
  7. Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodies. Ann Allergy Asthma Immunol. 2019 02; 122(2):213-215. View abstract
  8. A quality improvement initiative to increase access to food challenges. Pediatr Allergy Immunol. 2018 06; 29(4):447-449. View abstract
  9. The Role of Food Challenges in Clinical Practice. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):353-360. View abstract
  10. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):476-485.e3. View abstract
  11. Multicenter prevalence of anaphylaxis in clinic-based oral food challenges. Ann Allergy Asthma Immunol. 2017 10; 119(4):339-348.e1. View abstract
  12. Update on Potential Therapies for IgE-Mediated Food Allergy. Curr Allergy Asthma Rep. 2017 Jan; 17(1):4. View abstract
  13. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017 Mar; 139(3):873-881.e8. View abstract
  14. Implementation of a Standardized Clinical Assessment and Management Plan (SCAMP) for Food Challenges. J Allergy Clin Immunol Pract. 2017 Mar - Apr; 5(2):335-344.e3. View abstract
  15. A Screening Tool for Assessing Alcohol Use Risk among Medically Vulnerable Youth. PLoS One. 2016; 11(5):e0156240. View abstract
  16. Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review. Pediatr Allergy Immunol. 2015 Sep; 26(6):537-44. View abstract
  17. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015 Mar-Apr; 3(2):206-212.e4. View abstract
  18. Pediatric hereditary angioedema. Pediatr Allergy Immunol. 2014 Aug; 25(5):420-7. View abstract
  19. Use of ecallantide in pediatric hereditary angioedema. Pediatrics. 2013 Aug; 132(2):e490-7. View abstract
  20. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc. 2013 Mar-Apr; 34(2):155-61. View abstract
  21. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol. 2013 Mar; 110(3):168-72. View abstract
  22. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013 Mar; 110(3):184-188.e2. View abstract
  23. Long-acting beta-agonists and the risk of intensive care unit admission in children. J Asthma. 2012 Jun; 49(5):450-5. View abstract
  24. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics. Allergy Asthma Proc. 2012 Mar-Apr; 33(2):178-85. View abstract
  25. Infant with unusual food reactions. Acta Paediatr. 2011 Oct; 100(10):1289, 1394-5. View abstract
  26. Indoor allergen sensitization and the risk of asthma and eczema in children in Pittsburgh. Allergy Asthma Proc. 2011 Sep-Oct; 32(5):372-6. View abstract
  27. Successful use of ecallantide to treat a hereditary angioedema attack after failure of C1 inhibitor prophylaxis. Ann Allergy Asthma Immunol. 2011 Aug; 107(2):181-2. View abstract
  28. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol. 2011 Nov; 22(7):671-5. View abstract
  29. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol. 2011 Jan; 127(1):264-5. View abstract
  30. In utero anaphylaxis. Med Hypotheses. 2011 Jan; 76(1):70-2. View abstract
  31. Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13. J Allergy Clin Immunol. 2009 Oct; 124(4):761-70.e1. View abstract
  32. 11q terminal deletion disorder and common variable immunodeficiency. Ann Allergy Asthma Immunol. 2009 Sep; 103(3):267-8. View abstract
  33. Chronic granulomatous disease in an adolescent with recurrent impetigo and cholecystectomy. Pediatr Infect Dis J. 2009 Mar; 28(3):255-7. View abstract
  34. X-linked lymphoproliferative disease in an EBV-negative patient presenting with pancytopenia. Pediatr Blood Cancer. 2008 Jun; 50(6):1296-7. View abstract
  35. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol. 2003 Oct; 14(5):409-11. View abstract
  36. X-linked lymphoproliferative disease: genetic lesions and clinical consequences. Curr Allergy Asthma Rep. 2002 Sep; 2(5):361-7. View abstract
  37. Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. J Invest Dermatol. 1999 Aug; 113(2):162-9. View abstract
  38. A cytidine deaminase expressed in the post-infective L3 stage of the filarial nematode, Brugia pahangi, has a novel RNA-binding activity. Mol Biochem Parasitol. 1997 Sep; 88(1-2):105-14. View abstract
  39. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J Biol Chem. 1995 Jun 16; 270(24):14768-75. View abstract
  40. apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J Biol Chem. 1995 Jun 16; 270(24):14762-7. View abstract
  41. Apolipoprotein B messenger RNA editing: insights into the molecular regulation of post-transcriptional cytidine deamination. Curr Opin Lipidol. 1995 Apr; 6(2):70-4. View abstract
  42. The binding of apobec-1 to mammalian apo B RNA is stabilized by the presence of complementation factors which are required for post-transcriptional editing. Nucleic Acids Symp Ser. 1995; (33):99-102. View abstract